Sheila Jacobs

Treatment with the next-generation potent prostacyclin receptor agonist ralinepag reduced pulmonary vascular resistance compared with placebo in patients with symptomatic pulmonary arterial hypertension.

New-onset atrial fibrillation during suspected infection in patients meets the Sepsis-3 conceptual criteria of acute organ dysfunction associated with a high risk for mortality.

At a clinically relevant dose, RVX208 improved hemodynamics and reversed pulmonary vascular remodeling in certain pulmonary arterial hypertension models in rats.

Use of the dry powder formulation of treprostinil, known as LIQ861, has demonstrated safety and tolerability in patients with pulmonary arterial hypertension beyond 2 weeks.

The use of spectral-detector computed tomography offers a highly accurate method to diagnose chronic thromboembolic pulmonary hypertension.

Following the use of balloon pulmonary angioplasty, patients with inoperable chronic thromboembolic pulmonary hypertension had decreased mean pulmonary artery pressure, pulmonary vascular resistance, and mean right arterial pressure.

The risk for coronary artery disease in patients with asthma-COPD overlap syndrome who used statins was lower regardless of the duration of treatment.

Comprehensive assessments of exercise capacity and quality of life can be used to predict 2-year mortality in patients with pulmonary arterial hypertension.

The presence of primary hypertension does not appear to have an effect on the prognosis of postmenopausal osteoporosis.

Hypertension and diabetes are especially prevalent comorbidities in obese patients with chronic obstructive pulmonary disease.